三阴性乳腺癌分子分型及各分型治疗新进展
Molecular Subtyping of Triple-Negative Breast Cancer and the Latest Advances in Treatment for Each Subtype
摘要: 乳腺癌作为全球女性发病率最高的恶性肿瘤，虽然目前综合性治疗的方法显著降低了患者的死亡率，但仍有一部分患者尤其是三阴性乳腺癌(triple negative breast cancer, TNBC)的患者无法从现有的治疗手段中获益。大量学者通过对TNBC分子分型的深入研究，发现了免疫疗法有望填补化疗的不足，同时对TNBC的治疗现状及预后也可产生深远的影响。本文旨在对TNBC的分子分型及其治疗的最新进展做一综述。
Abstract: Breast cancer is the malignant tumor with the highest incidence among women in the world. Although the current comprehensive treatment methods have significantly reduced the mortality rate of patients, there are still some patients, especially those with triple negative breast cancer (TNBC), who cannot benefit from the existing treatment methods. A large number of scholars have deeply studied the molecular typing of TNBC, and found that immunotherapy is expected to fill the deficiency of chemotherapy, and at the same time, it can also have a far-reaching impact on the treatment status and prognosis of TNBC. The purpose of this paper is to review the latest progress in molecular typing and treatment of TNBC.
文章引用：马鑫, 李大钊, 吴耀禄. 三阴性乳腺癌分子分型及各分型治疗新进展[J]. 临床医学进展, 2025, 15(8): 144-150. https://doi.org/10.12677/acm.2025.1582211

参考文献

[1] Bauer, K.R., Brown, M., Cress, R.D., Parise, C.A. and Caggiano, V. (2007) Descriptive Analysis of Estrogen Receptor (ER)‐Negative, Progesterone Receptor (PR)‐Negative, and HER2‐Negative Invasive Breast Cancer, the So‐Called Triple‐Negative Phenotype. Cancer, 109, 1721-1728. [Google Scholar] [CrossRef] [PubMed]
[2] 翁剑华, 廖瑜玲, 许素真. 三阴乳腺癌BRCA1/2基因表达及其与临床病理特征的相关性[J]. 吉林医学, 2022, 43(5): 1180-1181.
[3] 贾实, 马瑶, 赵毅. 三阴性乳腺癌诊治若干进展[J]. 中国实用外科杂志, 2021, 41(11): 1243-1248.
[4] 蒋威华, 孙晓宏, 李涌涛, 等. 汉族与维吾尔族三阴性乳腺癌患者的流行病学特征差异[J]. 实用临床医药杂志, 2016, 20(7): 66-80, 85.
[5] 林洁, 林绍强, 卢运龙, 等. 三阴性乳腺癌的研究进展[J]. 右江医学, 2015, 43(6): 741-744.
[6] DeSantis, C.E., Ma, J., Gaudet, M.M., Newman, L.A., Miller, K.D., Goding Sauer, A., et al. (2019) Breast Cancer Statistics, 2019. CA: A Cancer Journal for Clinicians, 69, 438-451. [Google Scholar] [CrossRef] [PubMed]
[7] Lehmann, B.D., Colaprico, A., Silva, T.C., Chen, J., An, H., Ban, Y., et al. (2021) Multi-Omics Analysis Identifies Therapeutic Vulnerabilities in Triple-Negative Breast Cancer Subtypes. Nature Communications, 12, Article No. 6276. [Google Scholar] [CrossRef] [PubMed]
[8] 李智勇, 白雪. 三阴性乳腺癌分子分型的研究进展[J]. 新医学, 2018, 49(2): 77-81.
[9] Jiang, Y.Z., Ma, D., Suo, C., et al. (2019) Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell, 35, 428-440.e5.
[10] Turkman, Y., Sakibia Opong, A., Harris, L. and Knobf, M. (2015) Biologic, Demographic, and Social Factors Affecting Triple Negative Breast Cancer Outcomes. Clinical Journal of Oncology Nursing, 19, 62-67. [Google Scholar] [CrossRef] [PubMed]
[11] 王丽娜, 钟轩. 三阴性乳腺癌“复旦分型”有了智能方案[N]. 医师报, 2022-08-11(B06).
[12] 吴松阳, 江一舟, 邵志敏. 三阴性乳腺癌治疗进展[J]. 中国普通外科杂志, 2021, 30(5): 510-521.
[13] 周淑玲, 杨文涛. 三阴性乳腺癌的临床病理特征及分子研究进展[J]. 中国癌症杂志, 2013, 23(8): 603-608.
[14] 赵全铭, 杨洋. 晚期三阴性乳腺癌的药物治疗进展[J]. 中国临床药理学与治疗学, 2020, 25(4): 475-480.
[15] 谭莉, 周茜, 王艺蓁, 等. 三阴性乳腺癌的分子分型及应用[J]. 肿瘤防治研究, 2015, 42(3): 300-304.
[16] Telli, M.L., Timms, K.M., Reid, J., Hennessy, B., Mills, G.B., Jensen, K.C., et al. (2016) Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research, 22, 3764-3773. [Google Scholar] [CrossRef] [PubMed]
[17] 史润泽, 李志高. 三阴性乳腺癌各亚型精准医疗策略研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 529-533.
[18] 孙莉, 赵毅. 三阴性乳腺癌治疗的研究进展[J]. 现代肿瘤医学, 2019, 27(13): 2420-2424.
[19] 孙晓萌, 高社干. 三阴性乳腺癌的临床治疗现状及新进展[J]. 实用癌症杂志, 2020, 35(6): 1037-1039.
[20] Francica, P. and Rottenberg, S. (2018) Mechanisms of PARP Inhibitor Resistance in Cancer and Insights into the DNA Damage Response. Genome Medicine, 10, Article No. 101. [Google Scholar] [CrossRef] [PubMed]
[21] 徐倩倩, 王常珺, 孙强. 三阴性乳腺癌分子分型与个体化靶向治疗现状[J]. 中华肿瘤防治杂志, 2017, 24(11): 788-794.
[22] Caiazza, F., Murray, A., Madden, S.F., Synnott, N.C., Ryan, E.J., O’Donovan, N., et al. (2016) Preclinical Evaluation of the AR Inhibitor Enzalutamide in Triple-Negative Breast Cancer Cells. Endocrine-Related Cancer, 23, 323-334. [Google Scholar] [CrossRef] [PubMed]
[23] 秦岩, 石岩, 赵明慧, 等. 三阴性乳腺癌的分子分型及靶向治疗进展[J]. 肿瘤学杂志, 2017, 23(11): 1027-1031.
[24] Bergin, A.R.T. and Loi, S. (2019) Triple-Negative Breast Cancer: Recent Treatment Advances. F1000Research, 8, 1342. [Google Scholar] [CrossRef] [PubMed]
[25] 李昕宇, 刘强. 中国乳腺癌免疫治疗转化研究进展[J]. 中国肿瘤临床, 2022, 49(22): 1156-1160.
[26] 陈莉娜. 三阴性乳腺癌概述[J]. 徐州医科大学学报, 2019, 39(6): 470-472.
[27] 王奕琳, 毛晓韵. 三阴性乳腺癌中医药研究进展[J]. 辽宁中医药大学学报, 2022, 24(12): 129-132.
[28] 陈琳, 罗斌. 三阴性乳腺癌亚分型研究进展[J]. 中华肿瘤防治杂志, 2020, 27(20): 1683-1690.
[29] 龚莎, 陆元志. 三阴性乳腺癌免疫微环境及免疫治疗研究进展[J]. 生命科学, 2020, 32(7): 746-753.
[30] Gerber, B., Loibl, S., Eidtmann, H., Rezai, M., Fasching, P.A., Tesch, H., et al. (2013) Neoadjuvant Bevacizumab and Anthracycline-Taxane-Based Chemotherapy in 678 Triple-Negative Primary Breast Cancers; Results from the Geparquinto Study (GBG 44). Annals of Oncology, 24, 2978-2984. [Google Scholar] [CrossRef] [PubMed]
[31] Sikov, W.M., Berry, D.A., Perou, C.M., et al. (2015) Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-Per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology, 33, 13-21.
[32] 朱晔, 佟仲生, 赵伟鹏. 三阴性乳腺癌肿瘤新抗原相关研究进展[J]. 中国肿瘤生物治疗杂志, 2022, 29(2): 135-141.

为你推荐